Report Overview

UK Urothelial Cancer market size stood at around USD xx million in 2019 and is projected to reach USD xx million by 2028, exhibiting a CAGR of 9.4% during the forecast period.

UK has one of the finest healthcare systems in the EU region which enables it to provide quality healthcare to the individual citizens. Urothelial cancer is by far the most common form of bladder cancer in UK, accounting for over 90% of all new bladder cancers diagnosed, as per Action Bladder Cancer UK (ABC UK). Moreover, about 75-80% of patients that are newly diagnosed with bladder cancer have non-muscle invasive tumours. Numerous factors are affecting the prevalence of the urothelial cancer in the country including the increasing population and exposure to a specific type of chemicals among numerous others.



Market Driving and Restraining Factors

Driving Factors

The prevalence of urothelial cancer is more in men as compared to women in the country, owing to the history of men working in manufacturing plants, thereby exposing themselves to hazardous chemicals which is one of the main causes of the increase in the prevalence of the disease in the country.

Surging volume of patients suffering from urothelial cancer and high recurrence rate of patients, increasing prevalence of geriatric population in UK, rising emergence and priority of targetedtherapyamong biopharmaceutical companies, rising awareness among people for early diagnosis and treatment, increasing adoption of unhealthy lifestyle of the people are some of the major as well as vital factors which will likely to augment the growth of the urothelial cancer drugs market in the projected timeframe of 2019-2028. On the other hand, rising development of new novel drugs by variouspharmaceuticalcompanies along with surging levels of investment in research activities which will further contribute by generating massive opportunities that will lead to the growth of the urothelial cancer drugs market in the above mentioned projected timeframe.